Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
British Journal of Cancer|February 23, 2024
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitroQiyu Cao, Annika Hajosch, Richard Eric Kast, et al.
Nature Communications|October 24, 2017
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xLGeorg Karpel-Massler, Chiaki Tsuge Ishida, Elena Bianchetti, et al.
Critical Reviews in Oncogenesis|December 6, 2016
Cell Death Induction in Cancer Therapy - Past, Present, and FutureLisa Nonnenmacher, Sebastian Hasslacher, Julia Zimmermann, et al.
Cancer Letters|March 9, 2026
Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogrammingDanyang Shan, Chenfei Lu, Hang Yu, et al.
Cancer Metastasis Reviews|December 14, 2019
Compare and contrast: pediatric cancer versus adult malignanciesPatricia Kattner, Hannah Strobel, Nika Khoshnevis, et al.
Molecular Cell|August 10, 2022
Lactate is an epigenetic metabolite that drives survival in model systems of glioblastomaConsuelo Torrini, Trang Thi Thu Nguyen, Chang Shu, et al.
International Journal of Cancer|November 1, 2015
A paired comparison between glioblastoma "stem cells" and differentiated cellsMatthias Schneider, Stephanie Ströbele, Lisa Nonnenmacher, et al.
Oncotarget|February 11, 2016
Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptideCharles C Cates, Angelo D Arias, Lynn S Nakayama Wong, et al.
International Journal of Oncology|August 23, 2018
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cellsSebastian Hasslacher, Lukas Schneele, Sebastien Stroh, et al.
JCI Insight|March 14, 2024
OGDH and Bcl-xL loss causes synthetic lethality in glioblastomaTrang Tt Nguyen, Consuelo Torrini, Enyuan Shang, et al.
Pageof 9